{"id":"W3015065138","doi":"10.1007/s13555-020-00373-z","title":"Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Genzyme; AstraZeneca; Allergan; Ortho Dermatologics; LEO Pharma; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Novartis Pharmaceuticals Corporation; Dermira; Sun Pharma; Celgene; Sanofi; Galderma; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Genentech; Valeant Pharmaceuticals International; Amgen","keywords":"Secukinumab; Medicine; Disease; Intensive care medicine; Psoriasis; Psoriatic arthritis; Clinical trial; Immunology; Dermatology; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000710457,0.0008241173,0.001758016,0.002326356,0.0002903244,0.001010867,0.0008207005,0.001008341,0.003523735],"category_scores_gemma":[0.001501507,0.0003219739,0.00108424,0.002156335,0.0002881728,0.0009677021,0.0005247589,0.001240495,0.0008936091],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004978435,"about_ca_system_score_gemma":0.0009859772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009884858,"about_ca_topic_score_gemma":0.002055074,"domain_scores_codex":[0.9996512,0.00007376527,0.00008908012,0.00005397219,0.0001108772,0.00002115479],"domain_scores_gemma":[0.9993175,0.0004702479,0.00009322642,0.00001159581,0.00008484898,0.00002253196],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001185499,0.00005982705,0.0001884087,0.08291352,0.0002990075,0.0002114635,0.00007432742,0.0002702418,0.000573238,0.001039192,0.01494669,0.8993055],"study_design_scores_gemma":[0.00009644269,0.0002608884,0.001911395,0.08232598,0.001534519,0.004046449,0.0001788792,0.0002028678,0.0004848197,0.00170513,0.907211,0.00004159952],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006918159,0.9994735,0.00003605919,0.00007861057,0.00005926282,0.00000445276,0.00001044555,0.000002532723,0.0002660544],"genre_scores_gemma":[0.0004495399,0.999216,0.00008778796,0.00009972851,0.00004651316,0.000005239826,0.00001391538,7.343504e-7,0.00008059833],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003523735,"threshold_uncertainty_score":0.01178807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04918913432521317,"score_gpt":0.2794191380912929,"score_spread":0.2302300037660797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}